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1. Introduction 
The field of surgical pathology is diagnostic in nature and since its inception, has always 
supported the treatment of cancer. The manner by which tissues are processed may vary 
between institutions, but the vast majority utilize formaldehyde as the fixative of choice. 
This fixative allows for excellent architectural tissue preservation thereby enabling optimal 
microscopic examination, the foundation from which surgical pathology is based upon. 
From fixed tissue, cancers have been categorized, sub-typed and features enumerated to 
help elucidate the differences that exist between them. Classification schemes that include 
grading and staging systems have been incorporated in their examination and, when 
coupled with the patient’s clinical data, have been useful in prognostication and guidance of 
follow-up treatment. The development of immunohistochemistry has only served to further 
ingrain the importance of proper tissue fixation with cancer sample preparation. Yet, despite 
providing the basis for these invaluable contributions, the approach of fixing tissue 
biospecimens with formaldehyde has, in recent years, undergone criticism as being a 
suboptimal means of preservation when molecular analysis is desired from these specimens. 
Added to this are other pressures to develop novel approaches by which tissue 
biospecimens can be interrogated. Within the field of surgical pathology, it is becoming 
recognized that various pre and post fixation factors may contribute to negatively impact 
the overall integrity of the tissue biospecimen. Outside surgical pathology, the continually 
decreasing size of core biopsy specimens are minimizing the amount of tissue present for 
architectural evaluation. In addition, newer treatments are continually being sought in order 
to further personalize cancer treatment based on the type of tumor present in the tissue 
specimen. These forces are necessitating a re-evaluation of the entire established process of 
fixation, and whether alternative methods may exist or be developed that may be more 
amenable for both diagnosis and biospecimen integrity. In this chapter, the central role of 
tissue biospecimens for the support and guidance of cancer care are discussed, with an 
examination on how newer technologies and minimally invasive approaches will change the 
landscape by which these specimens will be processed. 
2. The history of tissue biospecimens in cancer treatment 
The examination of tissue through the microscope falls within the modern day purview of 
surgical pathology. Although this examination is now performed by pathologists, the 
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emerging field of surgical pathology in the 19th century began with surgeons. Before the 
widespread acknowledgement that microscopic examination of tissue was compulsory for 
an adequate diagnosis, surgeons were limited to the gross examination of specimens and 
their personal assessment and experience as to whether the extirpated specimen was benign 
or malignant (Gal, 2001). At that time, malignant tumors often ran their course, and their 
examination in the living patient limited to only observation at the gross, not microscopic 
level. In 1856 Rudolf Virchow published the first book on histopathology, introducing the 
world of microanatomy to the medical community. Observations from this book and those 
that followed slowly led to a newfound understanding that diseases of the human body 
could be correlated to findings at the cellular level. A number of discoveries and inventions 
in the 19th century also proved instrumental in providing the basis from which tissue could 
be reliably and widely examined by others under the microscope. These advances, like the 
invention of the microtome for cutting thin tissue sections and the discovery of natural and 
synthetic dyes like hematoxylin for the staining of nuclei and eosin for the cytoplasm of 
cells, allowed for the reproducible examination of tissue and the subsequent classification of 
organ structure. With these advancements, excised tissue was no longer discarded, but 
examined and documented. The first observations between malignant and benign tissues 
were recorded, with malignant cells described as being different in size and shape, not 
connected at their margins, possessing nuclei that varied in size and number and forming 
irregular edges at their juxtaposition with the adjacent normal tissue. In contrast, the cells of 
benign epithelial growths resembled each other in size and shape, had fairly homogenous 
appearing nuclei, were more cohesive along the edges of their cell borders and formed 
straighter lines (Rosai, 1997). With time, specimen processing and evaluation of the 
specimen became more standardized. Through correlation over time with the clinical 
outcome of the patient and with observations of similar tumors from other patients, these 
tissue biospecimens became the first to influence the treatment of cancer in patients. With 
improvements in surgical techniques, anesthesia and the application of antiseptic 
precautions, surgeons began to broaden the degree of surgical intervention they performed 
on patients. The development of the frozen section, wherein a portion of the specimen was 
excised and sent to the pathologist for evaluation intra-operatively, burgeoned and soon 
became integral to the cancer patient’s care. The rapid freezing and hardening of the tissue 
specimen enabled the cutting of thin sections that could subsequently be stained and 
evaluated under the microscope. The surgeon now could know if the excised margins of a 
tumor specimen still had tumor cells in them, allowing for an intra-operative decision as to 
whether additional sections were needed or not. For certain other tumors, determining the 
depth of invasion through the frozen section became integral in planning out the remainder 
of the surgical plan for the cancer patient. The processing of the biospecimen would evolve 
to include frozen section evaluation on some, and fixation with paraffin embedding on the 
majority of excised tissue specimens sent to the pathology laboratory. Through the 
microscopic examination of all the subsequent slides, the diagnosis that is formulated by a 
pathologist is based on the resemblance and similarities to an archival history of previously 
diagnosed specimens that have been correlated with clinical outcome.  This largely empiric 
system has served the medical community well, with the diagnostic information  rendered 
by the pathologist enough to guide the cancer patient’s care and estimate their prognosis  
(Kufe, 2003). 
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2.1 Early tools in the assessment of tissue and tumor biospecimens 
Along with hematoxylin and eosin, a number of other stains were specifically developed to 
help identify cell structure and determine cellular function, but in the process aided to 
further classify tissues and categorize tumors. Their development was spurred by the fact 
that, despite the enumeration of histologic criteria published and disseminated about 
specific diseases and tumors, reproducibility among the growing numbers of physicians that 
practiced pathology remained a problem. In order to engender consensus, a number of 
special stains were created through experimentation that would eventually serve to better 
delineate cellular structure, content and properties.  One of these stains, the Periodic Acid 
Schiff stain, allowed for the detection of the presence of carbohydrate macromolecules, a 
feature that would prove to be a useful ancillary aid to morphology in the differentiation 
between different types of tumors. For example, the identification of the Periodic Acid Schiff 
reaction in tumors known as small round blue cells can be helpful in leading to the correct 
diagnosis.  Positive staining material in rhabdomyosarcomas, Ewing’s sarcomas, malignant 
peripheral neuroectodermal tumors and germinomas can help distinguish them from other 
tumors with similar histologic features such as desmoplastic small round cell tumors, small 
cell mesothelioma, and a number of other tumors with small round blue cell morphology 
(Leuschner, 1996). This stain is particularly helpful in identifying Ewing’s sarcoma, due to 
the fact that over 80% of these tumors have been reported to contain glycogen within their 
cytoplasm. Other special stains, like the Mucicarmine and Alcian blue stains, were originally 
used to help characterize cells that secreted mucin, aid in the early differential diagnosis of 
tumors and determine if they were useful in identification of tumor origin for metastatic 
tumors (Johnson, 1963). These stains have persevered and have modern day utility in 
defining poorly differentiated tumors as being or not being adenocarcinoma and in 
distinguishing adenocarcinomas from poorly differentiated squamous cell carcinomas in the 
evaluation of lung cancers for the former stain, and as an aid in the detection of intestinal 
metaplasia in the medical condition known as Barrett’s esophagus for the latter stain 
(Wallace, 2009). Yet another special stain, the reticulin stain, showed initial promise for 
staining specific extracellular matrix constituents, namely the collagen type III fibers that 
comprise the stromal network in many different organs. It can be particularly prominent in 
the liver, as these fibers invest the hepatocytes that make up the hepatic plates, with normal 
hepatic plates being two cell layers thick or less. Reticulin stains help to define hepatic 
adenomas and hepatocellular carcinomas from normal liver, subtle changes not so obvious 
when examined by hematoxylin and eosin stains alone. In hepatic adenomas, they show an 
expansile growth pattern whereas in hepatocellular carcinoma they demonstrate an increase 
in trabecular thickness. To this day, the reticulin stain continues to be recommended as part 
of the evaluation of nodules within the liver (Lennerz et, 2009). 
Later, the development of the electron microscope, with its ability to probe sub-cellular 
structure, proved a boon to tissue diagnostics as it related to cancer treatment. Delivery of 
the correct diagnosis enabled a treating physician the opportunity to give the most clinically 
relevant care. Electron microscopy allowed for the visualization of subcellular organelles 
that could otherwise not be discerned using traditional light microscopy. When tumor tissue 
was examined at the electron microscopy level, the presence or absence of organelles known 
to be specific to certain cell types enabled the identification of poorly differentiated tumors 
whose cell of origin could not, at the time, be properly classified at the morphologic level.  
The electron microscope provided more definitive characterization of tumor subtypes than 
www.intechopen.com
 Current Cancer Treatment – Novel Beyond Conventional Approaches 
 
786 
histology and special stains. In the case of Ewing’s sarcoma, although it was known to be 
one of the tumors that possesses cytoplasmic glycogen, variability in the degree of 
differentiation could mean that their abundance may also be variable, and hence it was 
advised that the diagnosis of Ewing’s sarcoma should not be based solely on the presence of 
glycogen  detected by the Periodic Acid Schiff stain in tissue sections with the appropriate 
morphology.  One factor may have played a role in this ambiguity, was the type of fixative 
being used. Eventually it was determined that the best fixative for detecting glycogen in 
tissue sections was alcohol, and that fixation in formaldehyde resulted in variable 
preservation of this macromolecule (Llombaart-Bosch, 1996). Additionally, it was also 
learned that specimens that were poorly fixed could lead to a complete absence of detectable 
glycogen. In these cases, ultrastructural evaluation would prove to be helpful in establishing 
the correct diagnosis. In the case of Ewing’s sarcoma, examination at the ultrastructural level 
revealed the presence of two cell types, the primary cell referred to as the light  or principal 
cell, and a secondary cell referred to as the dark cell.  The principal cell was characterized as 
having homogeneously sized nuclei and ample cytoplasms, sparse numbers of organelles 
and abundant glycogen. The dark cells possessed elongated to ovoid nuclei with condensed 
chromatin, and  likened to involuting principal cells. The identification of these cells have 
helped to characterize Ewing’s sarcoma as different from other tumors possessing a similar 
histologic appearance, particularly olfactory neuroblastomas (Trump, 1983). Another 
instance where electron microscopy has impacted cancer care and proven integral to the 
proper identification of a tumor is in the case of poorly differentiated tumors of the pleural 
cavities. In these situations the differential diagnosis  revolves between poorly differentiated 
adenocarcinoma versus mesothelioma. An incorrect diagnosis of adenocarcinoma, when in 
reality a tumor is a mesothelioma, can result in an expensive and time consuming work-up 
and legal issues. For quite a while, electron microscopy was considered the gold standard in 
the diagnosis of mesothelioma. The presence of long, slender, sinuous, branching and bushy 
microvilli found on the cell surface at the ultrastructural level were reported as being 
pathognomonic features  for diagnosing mesothelioma (Velez, 2002). Taken altogether, the 
development of special stains and electron microscopy aided in leading to the further sub-
classification of tumor tissue biospecimens.  These tools were readily incorporated into the 
surgical pathology community and contributed to the early attempts to tailor patient cancer 
care. Despite the advances these tools brought to patient cancer care, their limitations would 
eventually become apparent with the development of a newer tool that would be introduced 
to the armamentarium of surgical pathology, immunohistochemistry.  
2.2 Immunohistochemistry and the beginning of the end for empiric medicine 
In the latter half of the 20th century the ability to exploit the specificity of the antibody-
antigen reaction was successfully transferred from the experimental laboratory to clinical 
specimens. This application began with the immunofluoresence technique.  However, the 
major liability with this approach was three-fold: the need for a specialized microscope with 
fluorescence capabilities; the pre-requisite for fresh frozen tissue samples; and poor 
morphologic resolution (Taylor, 1994). Over the period from the mid 1970’s to the early 
1990’s these obstacles were eventually addressed with the development of alternative, non-
fluoresence labels and the discovery of antigen retrieval. In the latter, the abolishment of the 
interfering formalin induced cross-links in fixed tissue specimens led to the widespread 
application of this technique, now called immunohistochemistry, to the vast archive of fixed 
tissue specimens banked in pathology departments. A period in the surgical pathology 
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community began anew, similar to the advent of special stains and electron microscopy eras, 
wherein panels of recently developed antibodies were tested against series of tissue and 
tumor specimens with the intent to identify and again better characterize human disease. 
This period, as with the introduction of all new tools in the fields of diagnostic pathology, 
was met with initial skepticism. However, one key difference that this new tool brought 
would emerge that would distinguish it from that of its’ predecessors in the care of cancer 
patients. The previous tools only enabled the observation of cellular organelles and 
cytoplasmic or nuclear constituents. The technique of immunohistochemistry, with the 
specificity of the antibody-antigen relationship, allowed unprecedented access to the 
macromolecules integral to the functions of the cell, proteins. Through subsequent 
investigations of an assortment of proteins by a myriad of different investigators, the era of 
Personalized Medicine, in terms of its current day namesake, was unceremoniously ushered 
in. It now became possible to identify the presence or absence of proteins in specific cell 
types and tumors. In contrast to traditional empiric medicine, immunohistochemistry 
allowed for the identification of a specific target molecule in specific cell types. In empiric 
medicine, not all patients will respond to a specific drug based on the absence of the 
knowledge if the cancer cells in a patient contained those proteins acted upon by the drug, 
or had only low levels of those targeted proteins. With the advent of 
immunohistochemistry, proteins that were involved in or acted to drive the process of 
oncogenesis could now be identified. This identification allowed for rational drug treatment, 
with therapy based on the presence of a target protein or molecule in a cancer patient 
identified by immunohistochemistry on the tissue specimens. This approach represents the 
potential to significantly improve cancer care, taking into account the fact that the efficacy of 
pharmacotherapy in oncology is less than 50% (Jorgensen, 2009). In the very least, this 
approach will help eliminate the administration of certain therapeutic agents to those cancer 
patients who would not benefit from a drug, based again on the absence of the targeted 
molecule or protein in the patient’s tissue specimen.  
Possibly the first successful implementation of Personalized Medicine can be attributed to 
the steroid receptor estrogen in human breast cancers. The observations in preceding 
decades by physicians and scientists that the growth of certain reproductive organ related 
tumors appeared dependent on sex steroids led to further direct investigations. Eventually it 
was borne out that certain tumors, like those of the breast, possessed large numbers of the 
estrogen receptor and thus could be targeted for endocrine therapy. Later it became 
apparent that the amount of estrogen receptors in these tumors could be variable, and that 
patients with estrogen receptor positive tumors tended to have a better clinical course than 
those patients with estrogen receptor negative tumors. It thus became imperative to be able 
to determine the estrogen receptor status in these patient’s tumors. The method that became 
the initial mainstay to assess estrogen receptor status was the steroid ligand binding assay 
and involved the homogenization of tumor tissue into a lysate that was then exposed to 
labeled estradiol. This assay however, lacked adequate specificity and sensitivity for the 
clinical setting. The major drawback of this assay was the fact that it was based on a tissue 
homogenate and was therefore without any correlative histologic picture. Thus the 
proportion of tumor cells to stromal cells, or the amount of necrosis present in the sample 
submitted could not be accounted for in the sample.  Additionally, improper collection of 
the sample, that is, prolonged procurement time leading to artificial loss of this labile 
receptor, could bias the final results.  With the concurrent progress in 
immunohistochemistry, the development of an antibody suitable to test on frozen, and then 
ultimately formalin fixed and paraffin embedded tissue became available that ultimately 
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showed suitable concordance with the steroid based assay (Ottestad, 1988).  
Immunohistochemistry, because it enabled visualization of the receptor status on glass 
slides, was relatively inexpensive compared to the ligand binding assay and could evaluate 
small tumors, gradually gained acceptance as a means to evaluate steroid receptor status in 
breast cancer patients. Currently, immunohistochemistry is the standard by which estrogen 
and progesterone receptor status are assessed. Their assessment in the breast cancer patient 
is integral in guiding that patient’s direction of clinical care, as endocrine therapy has 
proven to be of benefit only to those that have tumors that are estrogen receptor positive.  
However, recent emphasis on the importance of proper tissue handling has been raised 
again bringing back into focus the importance of the tissue biospecimen’s role in cancer care. 
A recent collaborative effort by the American Society of Clinical Oncology and College of 
American Pathologists has brought to light the startling finding that up to 20% of estrogen 
or progesterone receptor findings by immunohistochemistry may be inaccurate, either being 
falsely negative or falsely positive (Hammond, 2010). These findings were determined by 
taking the original results and testing the same tissue blocks at an experienced 
immunohistochemistry central laboratory for comparison. In order to rectify this problem, 
this collaborative group published recommendations for the optimal handling of extirpated 
breast cancer specimens that under present day methods of tissue processing, would result 
in reproducible inter-laboratory steroid receptor studies. In this instance, breast cancer 
tissue biospecimens play a continuing role in the guidance of clinical care and the quality 
assessment of diagnosis. 
The story of the Her-2 gene and the development of the humanized monoclonal antibody 
trastuzumab represents a case wherein tissue biospecimens aided in the rapid identification 
and confirmation of a targeted cancer therapy.  Through the use of tissue biospecimens, 
researchers were able to identify a subset of patients that overexpressed the gene product of 
the Her-2 gene. With clinical correlation, this subset was determined to be associated with a 
worse overall prognosis and a relative resistance to endocrine therapy (Press, 1993). But 
more importantly, the presence of this overexpressed protein meant that it defined a 
particular group of breast cancer patients who might benefit the greatest by the creation of 
an anticancer agent directed specifically at that amplified gene product.  The biotechnology 
company Genetech eventually developed a recombinant monoclonal antibody that fit within 
a specific extracellular cleft and effectively abrogated any further tyrosine kinase activity. 
An antibody was also subsequently developed that could be used on tissue biospecimens to 
detect this proteins presence in breast cancer cells. Through the use of banked tissue, this 
antibody was tested on breast cancer tissue biospecimens, the results from which produced 
an FDA approved assay. The publication of these results led to the ability for pathology 
laboratories, community in addition to academic, to incorporate this immunostain into their 
diagnostic regimen.  The broad use of this immunostain led to the findings that the 
prevalence of the HER2 gene amplification in the breast cancer population was consistently 
between 20 to 30 percent. Similar to estrogen and progesterone receptors, continued 
research in the field of biospecimen science led to the conclusion that approximately one 
fifth of all breast cancer tissue specimens immunostained for the Her-2 protein could be 
inaccurate (Wolff, 2007).  A number of sources for variation were identified, ranging from 
preanalytic (time to fixation, method of tissue processing, time of fixation, type of fixation), 
analytic (assay validation, equipment calibration, use of standardized laboratory 
procedures, training and competency assessment of staff, type of antigen retrieval, test 
reagents, use of standardized control material, use of automated laboratory methods) and 
postanalytic (interpretation criteria, use of image analysis, reporting elements, quality 
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assurance procedures). Due to the number of sources of variation and the influence they 
could have on the tissue biospecimen, a number of situations were enumerated that were 
grounds to not use immunohistochemistry to assess Her-2 protein levels. These exclusionary 
criteria included the use of any fixatives other than formalin, needle biopsies fixed for less 
than 1 hour, excisional biopsies fixed for less than 6 hours and longer than 48 hours, core 
needle biopsies with edge or retraction artifact affecting the entire core or with crush 
artifact, tissues with strong membrane staining on internal normal ducts or lobules and 
tissues with controls that showed unexpected results. The initial and continued use of tissue 
biospecimens to assess Her-2 overexpression have been integral in creating appropriate 
standards aimed at establishing a uniform, reproducible result. In turn, these results 
continue to help further refine the clinical decision process in the care of breast cancer 
patients.  
The use of tissue biospecimens also played a significant role in expanding the utility of 
certain drugs in the treatment of cancer. Imatinib mesylate (Gleevec), originally designed to 
target the chronic myeloid specific protein BCR-ABL, was later found to show some activity 
with another tyrosine kinase, notably the gene product KIT. Using tissue biospecimens, 
investigators were able to document that a relatively rare gastrointestinal tumor, called a 
Gastrointestinal Stromal and Tumor, expressed the KIT gene (Hirota, 1998). Treatment of 
Gastrointestinal Stromal patients with this therapeutic agent produced remarkable results. 
These previous examples illustrate how tissue biospecimens have helped shape the 
development of therapeutic agents for the treatment of cancer. A known protein that can be 
targeted is identified, a potentially therapeutic agent created or already is in existence, and 
assays developed that can identify those protein(s) on tissues.  The changing paradigm is to 
treat a patient’s tumor with an agent that is antagonistic to a protein or molecule that can be 
documented to be present in the tumor tissue. This is in contrast to treating the tumor based 
on a histologic classification and previous experience of response in a certain percentage of 
patient’s with that tumor type. In this new era of Personalized Medicine, therapies will be 
given specifically to those individuals most apt to respond to them. Therefore, those who 
will benefit from a targeted therapy will be appropriately selected for treatment, and those 
who will not benefit will be treated by another regimen. Tissue biospecimens will continue 
to play a significant role in the new medical paradigm, however their traditional role may 
evolve. Whereas the current means of evaluating tissue biospecimens is after fixation and 
processing, with the end result a paraffin embedded specimen that is stained for visual 
examination either through traditional hematoxylin and eosin stains complimented by 
immunohistochemistry, tomorrow’s biospecimen may be subjected to molecular assays. A 
representative scenario is the case of CD-117 positive tumors. Initially, Gastrointestinal 
Stromal Tumors were found to express this protein in abundance. By similar reasoning, it 
was assumed that other CD-117 positive tumors could also be treated by this tyrosine kinase 
inhibitor. A number of CD-117 positive tumors were rapidly identified that included 
colorectal cancers, renal cell carcinomas, thymic epithelial tumors, seminomas, Merkel cell 
cancers, endometrial stromal sarcoma and aggressive fibromatosis (Quek, 2009). However, 
the clinical community soon came to the realization after much scientific investigation that 
the underlying molecular alterations in Gastrointestinal Stromal Tumors, namely the gain of 
function mutations in the C-Kit gene in specific exons, were the underlying reason for their 
therapeutic responsiveness. Although other tumors may express the C-Kit gene product and 
can be readily identified as being CD-117 positive, without the specific mutations seen in 
GIST tumors, these other tumors turned out to be non-responsive to Gleevec administered 
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therapy. This example highlights how the oncoming molecular age in medicine will play a 
role in the analysis of biospecimens for the rational delivery of targeted therapy.   
3. Achieving personalized medicine through improved diagnostics 
Although conventional light microscopy has been the stalwart of diagnostic pathology for 
decades, it continues to have problems with reproducibility among members of its 
collegium. As a continually evolving field, newly described entities go through the academic 
rigors of debate before consensus is reached. This can take some time, with consensus 
established after many years. Several examples showcase the limitations of diagnosis based 
solely on morphology. In the colon, preneoplastic polyps have traditionally been classified 
as either hyperplastic or adenomatous. In the late 1990’s, two new entities were described 
called the serrated adenoma and the admixed polyp. Despite a decade where these entities 
were studied and further described, some confusion still remains regarding their correct 
diagnosis. When specialist gastrointestinal pathologists were shown a number of cases of 
these two entities, only a moderate degree of concordance was noted, and only fair inter-
observer agreement evident (Wong, 2009). When cells alone are examined, that is, in the 
form of a cytology specimen, molecular diagnosis can be an improvement. The detection of 
atypical cells in sputum cells prepared for cytologic examination for the screening of lung 
cancer is a proven method, but suffers from low sensitivity. The addition of genomic 
markers can raise the sensitivity of cancer detection to 86% and specificity to 93% (Jiang, 
2010). When it comes to actual tumors, interobserver agreement has had a history of similar 
problems with at best, modest reproducibility. One of the more difficult tumors to classify 
are those epithelial tumors originating from the ovary. Through decades of examination, 
diagnostic reproducibility based on morphology has steadily increased (Kobel, 2010). 
Aiding this improvement has been immunohistochemistry and molecular analysis. There 
are now considered to be five major subtypes of ovarian carcinoma: high grade serous, clear 
cell, endometrioid, mucinous and low grade serous carcinoma. The importance of this new 
paradigm based classification again is treatment based, with high grade serous being 
responsive to neoadjuvant chemotherapy whereas the others are not. From continued 
research utilizing all available data from the patient, the clinical outcome and most 
importantly the tissue, consensus in diagnosis is being achieved with diagnostic algorithms 
to achieving reproducible results being reported (Kalloger, 2011).  
These examples demonstrate the limitation of histologic diagnosis and the increasing role 
molecular analysis will play in identifying, classifying and prognosticating tumors. Assays 
that will be developed to achieve this will most likely be used to interrogate nucleic acids, 
whether DNA or RNA, but may also analyze proteins. The arrival of these assays may be 
tied directly to therapy and hence have been given the designation companion diagnostics 
(Papadopoulos, 2006). The implications of using these molecular approaches are that they 
may eventually yield more informative data than conventional hematoxylin and eosin 
stained microscopic slides, even when the tissue is further worked up with 
immunohistochemistry. The goal is to be able to identify subgroups within a given patient 
population whose histology may appear similar, but end up having a different clinical 
course or outcome. It is hoped that through the molecular evaluation of tissue specimens, 
molecular signatures can be identified and assays developed that can recognize and 
separate these subsets of patients from the general cancer population. A realistic future 
scenario where molecular studies may eventually take precedence over histology is with 
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Stage II and III adenocarcinoma of the colon. Although histologically these tumors may 
appear morphologically similar and stage similarly, it is known that a certain proportion of 
these patients do benefit from adjuvant chemotherapy whereas for the other proportion of 
this group it is unnecessary. The identification of a biomarker or biomarkers capable of 
clearly delineating these two subpopulations would save time, effort and benefit the 
patients having to be and those not having to be treated. Another reason molecular analysis 
may be more informative than traditional hematoxylin and eosin stained sections is its 
objective nature. There are a number of tissue types from  which human bias has been 
known to exist. The classification of dysplasia in the oral-pharyngeal space has for years 
been known to suffer from inter- and even intraobserver variability (Karabulut, 1995 and 
Abbey, 1995). For gliomas of the brain,  histologic classification, which guides subsequent 
therapy, suffers from interobserver variability (Kros, 2007).  Even with an updated 
classification scheme, diagnostic variability persists now due to the addition of newly added 
entities and variants (Tremblath, 2008). It would appear logical then, that another 
mechanism of diagnosing these types of tumors would be attempted. In fact, a recent study 
did find that molecular analysis did perform better than traditional histology, albeit in the 
realm of survival prognostication  (Gravendeel, 2009).  Thus it appears that with the 
molecular era steadily encroaching the clinical realm, the dedication of a proportion of 
tissue from excised tumor biospecimens may be needed as part of the standard of care for 
the cancer patient. The tissue biospecimen will still be integral in patient care, but the 
manner by which it is examined will evolve. 
4. Barriers to the molecular profiling of clinical specimens - formalin fixation 
Several barriers exist that limit the application of molecular techniques to tissue 
biospecimens. Since the main goal of extirpated tissue is the establishment of a diagnosis, 
the priority for such specimens is the optimal preparation of a tissue section for 
morphologic evaluation. In order to do this, tissue preparation involves fixation and 
processing, followed by sectioning and staining for microscopic examination. In the vast 
majority of community and academic pathology departments, the fixation used is 10% 
neutral buffered formaldehyde. Whereas this fixative results in a reliable and reproducible 
end product for histologic examination, it has been shown to be detrimental to the recovery 
and examination of cellular molecules. Formaldehyde interacts with DNA  to create 
hydroxymethyl groups, forms methylene bridges between amino acids, generates apurinic 
and apyrimidic sites that lead to highly unstable cyclic carboxonium ions that hydrolyze 
into 2-deoxy-D-ribose, and cause the slow hydrolysis of phosphodiester bonds that result in 
short chains of polydeoxyribose with intact pyrimidines. In short, the chemical reaction 
between formaldehyde and deoxyribose nucleic acids leads to the denaturation of these 
molecules as well as the formation of cross links with proteins. The result is the recovery of 
shortened segments or fragmented DNA and decreased recovery. For certain high 
throughput downstream molecular based assays, like array comparative genomic 
hybridization that are designed to evaluate the copy numbers of genes from the entire 
genome, the absence of gene segments may lead to erroneously biased conclusions relating 
to genetic deletions. Several reports have noted that DNA extracted from formalin fixed, 
paraffin embedded tissue blocks and run on an array comparative genomic hybridization 
platform, tended to yield data prone to spurious changes in genetic copy number in 
addition to copy number loss when compared to matched fresh frozen tissue (McSherry, 
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2007).  To complicate matters worse, the presence of formaldehyde results in the presence of 
high background ‘noise’ on array comparative genomic hybridization data, making the 
determination of legitimate significant molecular alterations problematic (Johnson, 2006 and 
Mojica, 2008). At the nucleotide level, formaldehyde has been documented to result in 
random changes in amplified sequences relative to the original DNA sequence. Formalin 
fixation is thought to cause base damage, but the overall template can still be read by 
polymerases.  When PCR is performed using Taq polymerase, errors in translesional 
synthesis can occur (Quach, 2004). Although this error rate is low, it can be a factor when 
small amounts of originating material are used. This has grave implications at the clinical 
level, as the reporting of non-existent mutations may severely impact a patient’s care 
altering the treatment regimen from which the fixed tissue originated from.  
RNA is another potential biomarker that can be assayed from tissue biospecimens, and in 
the past decade has already influenced the realm of pathologic diagnostics in the field of 
breast cancer. Through expression array analysis, breast cancers now are considered to 
comprise a number of subgroups (normal-like, luminal, basal-like, HER-2(+))  within the 
broad spectrum of what was originally only considered part of one entity, ductal 
adenocarcinoma. Work is currently progressing on finding the most appropriate therapeutic 
regimen for each subtype. Based on the clinical success of this molecular based classification, 
other tumors are being probed for their molecular signature. However, it must be noted that 
the original work that defined these breast cancer subtypes was based on fresh frozen 
material. Any subsequent discoveries on such tissue must be able to be translated to clinical 
material, which again routinely undergoes formalin fixation and processing. Similar to 
DNA, mRNA recovery from FFPE tissue is encumbered by the crosslinking of molecules 
and poor recovery (Cox, 2006). But since mRNA is a more labile molecule than DNA, 
degradation of the RNA molecule impacts the overall recovery more with significantly 
reduced quantities and poor quality obtained from fixed tissue specimens when compared 
to matched frozen material (Specht, 2001). This negatively impacts the consideration of 
using FFPE tissue biospecimens for gene expression on cancer samples.  RNA extracted 
from FFPE tissue is partially degraded resulting in gene expression data with low signal 
intensity data. In one study, only a quarter of unselected samples that were FFPE provided 
enough starting material for subsequent gene expression assays (Penland, 2007). In another 
study, gene expression values differed by a value greater than two fold in almost 20% of the 
genes studied between matched FFPE and frozen tissue samples (Mojica, 2007). This rather 
significant discrepancy can be accounted for by either a decrease in gene expression due to 
degradation or an increase in gene expression due to changes in the tissue 
microenvironment and the cells subsequent reaction prior to fixation. The major implication 
however, in regards to human tissue that could be potentially assayed for mRNA expression 
levels that may influence clinical care, is to determine beforehand which mRNA transcripts 
are stable, and remain stable. It is these transcripts that would be of clinical value, as 
opposed to those more labile ones prone to either degradation or biased due to ex vivo 
conditions (Lee, 2005). This obviously would require an in depth investigation into which 
transcripts are most stable and least resistant to the external pressures associated with the 
tissue fixation process, so that those that are susceptible to degradation during the process 
of fixation are excluded from further consideration and studies (Opitz, 2010).  
Proteins are the last major molecule to be mentioned here that are routinely assayed from 
clinical tissue biospecimens. The formalin-fixed, paraffin-embedded tissue specimens 
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routinely examined in surgical pathology departments currently undergo proteomic 
evaluation in the form of immunohistochemistry. However, this analysis is often limited to 
evaluating only one, or at most two proteins in the tissue section. When tissue biospecimens 
are exceedingly small, the tissue may get exhausted, limiting the number of proteins that 
can be examined through immunohistochemistry. An approach that may see increased use, 
especially when a number of proteins will need to be evaluated in a tissue biospecimen, is 
mass spectrometry. Currently, mass spectrometry is finding initial success as a diagnostic 
modality for amyloidosis, and its integration into other pathologic conditions most likely 
will soon follow suit. However, as with DNA and RNA, the analysis of the traditionally 
formalin-fixed, paraffin-embedded tissue biospecimen by mass spectrometry will present 
with problems once again associated with formaldehyde. The cross links formed in proteins 
increase the complexity of data analysis and peptide identification through the addition of 
12 and 30 Dalton changes in the peptide mass (Metz, 2006). Adding to the complexity of this 
reaction is the finding that with time, more methylene bridges (cross-links) are formed 
creating increases in the molecular weight of a peptide by multiples of 12  Daltons (Toews, 
2008). Chemical reactions that occur with cross-linked peptides can result in incomplete 
fragments upon collision-induced dissociation, requiring additional targeted experiments to 
correctly identify those peptide fragments (Sutherland, 2008). This necessitates the creation 
of specialized software that takes into consideration these mass effect changes before correct 
peptide identification can be made, a daunting task considering the multitude of 
combinations possible due to fixation (Leitner, 2010). The presence of cross links may also 
result in intra-protein peptide combinations as well as portions of peptides between 
different proteins, making an already difficult task even more complicated. Research into 
the mass spectrometry analysis of formalin-fixed, paraffin-embedded tissue has shown that 
comparable data with matched fresh frozen material can be done using principles learned 
from antigen retrieval and immunohistochemistry. The original findings that compared the 
numbers of proteins identified by mass spectrometry analysis between matched formalin 
fixed, paraffin embedded and frozen tissue sections showed the former to consistently be 
quantitatively less than the latter (Crockett, 2005, Bagnato, 2007 and Guo, 2007). Despite 
claims touting the feasibility of mass spectrometric analysis on formalin-fixed paraffin-
embedded tissue, complete concordance of protein inventories with matched frozen tissue 
has yet to be achieved, leading to speculation that material not detected from formalin-fixed, 
paraffin-embedded tissue may be due to incomplete lysis of cross links and either 
incomplete or biased protein extraction (Nirmalan, 2008). Research on fixed biospecimen 
material continues with the goal that either a mechanism of improved recovery will be 
found, a more molecular friendly method of fixation developed, or an alternative means of 
diagnostics created that is compatible with both surgical pathology and molecular assays. 
4.1 Barriers to the molecular profiling of clinical specimens - preanalytical variables 
Complicating the implementation of molecular analysis on fixed tissue biospecimens is the 
growing awareness that a number of preanalytical factors may unduly influence the 
characteristics of certain molecules prior to fixation. Since the intent of assaying a tissue 
biospecimen is the characterization of molecules reflective of a cancer cells’ in vivo state, it 
stands that any factor that alters that state is undesirable. Unfortunately, a number of factors 
have now been recognized that may introduce unintended molecular variation to the 
biospecimen and include the type of surgical procedure, warm and cold ischemia, time to 
fixation, tissue thickness and rate of fixative penetration. These variables predominantly 
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affect the most labile molecules, namely mRNA and protein phosphorylation status 
(Sprussel, 2004 and Espina, 2008) and occur early in the procedure (Miyatake, 2004 and 
Schlomm, 2008). The first of these variables, the type of surgical procedure, can influence a 
cell’s molecular signature due to the initiation of hypoxia. As the specimen is being excised, 
vessels are sequentially ligated before the entire specimen is ready to be extirpated. The type 
of procedure can influence the molecular signature, as the shorter, quicker procedure will 
have less of an influence than procedures that take longer, time wise. An approach that is 
becoming more popular because it is less invasive and therefore results in a shorter hospital 
stay, is laparoscopic surgery. For resections of colon cancer specimens, the durations of 
surgery increases 55 minutes from that of an open surgical resection (COSTG, 2004). With 
the introduction of robotic assisted surgery, a procedure rising in popularity because of 
benefits like less blood loss for the patient, the duration of ischemia can increase between 30 
minutes to 1.5 hours in prostatectomy specimens. These short changes in time may not be 
significant enough to change  the levels of proteins, but can unduly influence the expression 
profile signatures of the more labile mRNA transcripts (Ricciardelli, 2010). This increase is 
attributable to a reversal in the sequence of vessel ligation, where in robotic assisted 
prostatectomy procedures they are done earlier as opposed to later, as in open 
prostatectomies. Whereas these changes occur prior to the acquisition of the tissue by the 
department of pathology, other variables influence the molecular signature of cells within 
tissue post-acquisition. Cold ischemia, or the time the tissue is outside of the body and either 
frozen or fixed, is the major factor in determining the adequacy of the tissue for further 
analysis. Although not incorporated into many protocols, the time from receipt to freezing 
has a strong negative impact on the molecular profile of the tissue specimen (De Cecco, 
2009). For tissue that undergoes fixation, the cold ischemia time is longer. For these 
specimens, once they are received within the department of pathology, they are immersed 
in 10% neutral buffered formalin. The cells within the tissue however, will remain viable for 
a limited time, most likely until they become fixed. The cells are now enduring a loss of their 
blood supply, accumulation of lactic acid with the subsequent decrease in their cellular pH, 
and changes in temperature (room temperature vs. in vivo body temperature), all resulting 
in biologic stress. In response to this biologic stress, they will react, and in the process their 
molecular signature will be altered to some degree to this stress. The obvious conundrum is 
to determine what of the molecular signature can be considered artifactual, i.e., as a 
complication of this artificially induced stress, and what can be characteristic of the 
neoplastic state. An added layer complicating these changes is the fact that tissue thickness 
can lead to regional differences in the specimen’s molecular profile. Formalin infuses into 
tissue at 1 mm an hour. If specimens are not sectioned before they are placed in a container 
of formalin, the tissue at the center of the specimen will be fixed last relative to the exterior 
of the specimen. Since the cells in the tissue are still viable until fixation, the cells within the 
center of the specimen will be responding to their new environment (Stan, 2006). Depending 
on their distance from the fixative, these cells will experience progressively hypoxic, acidic 
and nutrient depleted conditions over time (Espina, 2008 and van Maldegem, 2008). As 
viable cells now under biologic stress, their molecular profile may alter leading to falsely 
elevated or decreased levels of a putative biomarker relative to those cells in direct initial 
contact with formaldehyde. The basic tenet when working with clinical specimens is to 
realize that excised tissue is viable and not only vulnerable but reactive to ex vivo stressors, 
and that an understanding as to their location within the specimen with respect to exposure 
to fixative should be considered in the data analysis (Espina, 2008).  
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These preanalytical factors have the potential to lead to significant variability in the 
molecular signature of cells within a tissue specimen. Although there exists numerous tissue 
biorepositories within the United States, a major problem with each is the wide variation in 
tissue collection, processing and storage of these samples and an absence of standardized 
procedures for each step (National Biospecimen Network Blueprint, 2003). The development 
of a sample preanalytical code proposed by the International Society of Biospecimen and 
Environmental Repositories represents a good start towards standardization (Betsou, 2010). 
Through the compilation of data from tissue biospecimens, and correlation with this 
proposed grading system of specimen integrity, the factors that play into macromolecule 
integrity can be identified. Each organ may exhibit differences in the stability of the 
molecules within their cells, with those possessing digestive type enzymes (e.g., the 
pancreas) more labile than those without (e.g. skeletal muscle). A previous study indicated 
that the biopsy, based on the smaller tissue size and exposure to the shorter periods of warm 
or cold ischemia, to be the optimal tissue biospecimen for molecular analysis. The small size 
of the biopsy allows for even exposure to fixative, while the actual procedure of acquiring 
small pieces of  tissue are not encumbered by extensive periods of surgically induced 
ischemia required to excise a diseased organ nor intraoperative procedures that are deemed 
clinically imperative to the needs of biospecimen collection (Schlomm, 2008 and Espina, 
2008).  
4.2 Barriers to the clinical profiling of clinical specimens - tissue heterogeneity  
Another barrier to molecular profiling of clinical tissue biospecimens is tissue heterogeneity. 
Human tissue specimens are increasingly being used as the primary source of 
investigational material for cancer related studies. They offer advantages over cells lines 
because they are more representative of the diagnosed condition and reflective of the in vivo 
condition, not having undergone numerous passages and the resultant phenotypic and 
genetic drift. Properly collected and annotated, they can avert the problems of 
misidentification, a relatively widespread situation wherein certain cell lines actually 
correspond to other cell types than what they are designated to be (Buehring, 2004)). Despite 
extensive work on cell lines, the realization that the cell of origin may actually be a 
contaminant would be disastrous for any investigator. However, using tissue itself is 
fraught with problems. The integrated architecture of tissue means that the targeted cell of 
interest will vary with respect to the overall cell volume, even in normal tissue (Figure 1).  In 
tumor samples, the same problem exists (Enkemann, 2010). Depending on the type of tumor, 
the percentage of non-tumor cells can also be less than 50%. Although in grossly solid areas 
of tumor tissue colon cancer, lung cancer and breast cancer can compromise over 80% of the 
tumor, prostate cancer is notable for interdigitating between normal glands, possibly biasing 
any subsequent findings based on such a tissue biospecimen (Figure 2). The presence of 
contaminating normal cells in a tumor sample can have the affect of dampening a signal or 
mask the detection of a potential biomarker molecule. The presence of segments of nucleic 
acids originating from contaminating normal cells can have the untoward affect of 
decreasing the amplitude of a deleted gene in a tumor sample (Mojica, 2007). Ideally, any 
work done on a sample should ensure that it is a pure, or close to pure cell population of the 
desired cell type, so that retrospective analysis trying to deconvolute the data does not have 
to be performed (Tureci, 2003 and Shen-Orr, 2010). The development of the laser capture 
micro-dissection tool has provided an answer to tissue heterogeneity. With this machine or 
one of its congeners, specific cell types can be visualized, identified and then procured,  
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Fig. 1. Histology of normal colonic mucosa. The glands and surface consist of epithelial cells, 
while the lamina propria contains chronic inflammatory cells. Interspersed in the mucosa 
are lymphoid aggregates (left side of figure), which cannot be readily discerned at the gross 
examination level. Without microscopic examination, the proportion of targeted cells, in this 
case colonic epithelial cells, could account for less than 50% of the cells in sample. 
Hematoxylin and Eosin stain, 10X 
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Fig. 2. Histology of prostate cancer. Tumor is in the upper right hand corner, while normal 
glandular prostatic cells and stroma make up the remainder of the specimen. Hematoxylin 
and Eosin stain, 10X. 
leaving the unwanted contaminating cells with the tissue. It works for both frozen tissue 
specimens and formalin fixed paraffin embedded tissue. A major drawback with its use 
however, is the time consuming nature of manually procuring the wanted cells. This issue 
has been addressed with the development of automated programs, that coupled with cell 
recognition software, have alleviated the overall time needed to select cells from tissue 
specimens. The other major drawback with this instrument has been its high start-up cost. 
Most machines have a six figure price tag, but newer, cheaper versions have been 
developed. An alternative method has been the use of immunomagnetic beads for the 
recovery of targeted cells (Mojica, 2006).This approach starts with fresh tissue specimens, 
that is, before they are fixed, and after a series of manipulations, recovers a highly enriched 
collection of cells. This method is cost effective, and does not involve any significant 
expenditure. It has advantages over using straight (un-enriched) biopsy samples in that it 
can enrich for a targeted cell population. Simple adjustments to the procedure can  
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Fig. 3. Cells exfoliated from colonic tissue with no enrichment. Note presence of red blood 
cells and mucus. Hematoxylin and Eosin stain , 40X.  
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Fig. 4. Recovered cells from enrichment described in text. Yellow dots are immunomagnetic 
beads. Hematoxylin and Eosin stain 40X 
targeted cell population. Simple adjustments to the procedure can be made to eliminate the 
presence of red blood cells, whose presence is significant in tissue biospecimens (Figure 3). 
This is particularly important for proteomic, and not so much for nucleic acid studies, as red 
blood cells have a number of proteins within their cytosol that may contribute to complicate 
any subsequent un-enriched lysate (Pasini, 2006, and D’Alessandro, 2010). The result of such 
enrichment is an expansion in the detection of the proteins from the targeted cell (dePetris, 
2010). The use of several washes helps eliminate the presence of other contaminating 
substances, using as an example, excess mucus from colon specimens. Mucus itself is not 
detrimental to downstream analysis, since it is the secreted product of certain types of 
colonic epithelial cells. It is however, the location whereby commensal organisms like 
bacteria habitate, and their inclusion in any sample for downstream analysis could lead to 
confounding genetic or proteomic results (Qin, 2010). Since the technique can be done on 
fresh tissue specimens, the problems associated with formalin enumerated earlier are not 
encountered. Finally, the use of the ber-Ep4 immunomagentic beads are commercially 
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available and have been for several years. As ber-Ep4 recognizes an epitope in epithelial 
cells, this method works nicely as a means for their procurement from specimens with the 
intent to isolate epithelial cells from the underlying tissue (Figure 4). The overall technique 
however, is not restricted to ber-EP4, as other antibodies with specificities to other cell 
surface membrane proteins can be conjugated to the magnetic beads. One of the limiting 
factors however, is the relative paucity of antibodies available to select from that may be 
used to positively enrich for a specific cell type from a heterogeneous population. This 
dearth is attributable to the limited knowledge of the proteome of the plasma membrane, 
which in turn is due to the difficulties associated with examining molecules with 
hydrophilic and hydrophobic properties. When the plasma membrane proteome is not 
known for a specific cell type, an alternative but reportedly equally effective approach 
would be through negative enrichment, where contaminating cells are targeted and 
removed from the sample population.  This has been used for the examination of sputum 
with respect for lung cancer diagnosis (Qui, 2008). In cytology, the presence of pulmonary 
macrophages is essential to document that the material has cells from the lung, and not just 
the oral cavity. These same cells however, would contribute to the heterogeneity of the 
sample for any subsequent molecular analysis. Their selection, and that of neutrophils using 
anti-CD-14 and anti-CD-16 immunomagnetic beads can lead to a significant improvement in 
the numbers of bronchial epithelial cells recovered. An alternative to using antibodies are 
aptamers. Aptamers are short single stranded nucleic acid oligomers that can take on a 
variety of three dimensional shapes, thus allowing them to bind to a wide variety of 
molecules, with binding affinities similar to monoclonal antibodies (Kim, 2009). One 
advantage of using aptamers over antibodies is their relative stability. Another is the ability 
to work with cells without knowing specific proteins. This approach would thus be an 
alternative to the extensive plasma membrane profiling that would be required in order to 
identify differentially expressed proteins between normal and tumor cell populations.  
5. The advent of molecular analysis in cancer tissue specimens 
Despite all these roadblocks to using clinically derived tissue specimens for molecular 
analysis, their use in clinical cancer care already exists. A perfect example is the use of 
monoclonal antibodies created to antagonistically bind and inhibit the plasma membrane 
protein Epidermal Growth Factor Receptor  (EGFR) in colorectal cancer and non-small cell 
lung cancer (Plesec, 2009 and Wang, 2010). Although the EGFR receptor can be recognized 
by immunohistochemistry in tissue specimens, this assay has been found to not be a reliable 
means of determining those likely to respond to this type of therapy. However, the 
identification of those patients most likely to respond is imperative in order to avoid any 
unnecessary side effects, treatment related costs and delays in the administration of a more 
effective therapy. Since immunohistochemistry was deemed unreliable as a mechanism that 
could select patients for EGFR therapy, downstream components of the EGFR signaling 
cascade were examined. The result of these investigations was the finding that mutations in 
the KRAS gene could  identify those patients who would not be responsive to monoclonal 
antibody therapy directed at the EGFR receptor. In unselected patients, the number of 
patients that responded to cetuximab, the antibody directed against EGFR, was between 10-
20%, but when patients were selected for treatment based on the criteria of no KRAS 
mutations, this percentage rose to 60%. The detection of these mutations can be 
accomplished by a number of different methods, the common denominator being that they 
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evaluated the DNA sequence of the KRAS gene within tumor cells. The issues previously 
described associated with DNA and formalin fixation now have practical clinical relevance. 
Again, these issues relate mostly to template degradation and tissue purity.  For the former, 
the amplified product must be designed to be small enough to account for degradation yet 
long enough to enable specificity. For tissue purity, most laboratories require the tumor 
component in the tissue to be equal to or greater than 75%. The presence of contaminating 
normal cells raises the possibility that the DNA from these cells may be assayed instead of 
the tumor cell’s DNA, resulting in a normal sequencing electropherogram or false negative 
finding for the relevant mutations.  In some specimens the amount of contaminating normal 
cells is significant, and although laser capture microdissection can be used, the transference 
of this predominantly research tool to the clinical setting is prohibitive due to its labor 
intensive nature. A promising approach is the technique of “cold-PCR”, wherein mutant 
alleles in tumor cell can be amplified and subsequently sequenced when specific alleles from 
these tumor cells comprise only a minority population in a tissue sample (Li, 2008). A recent 
report documented the ability to detect mutations in tumor cells when they constitute only 
20% of the tissue sample using the technique of Cold-PCR (Yu, 2011). If no other 
developments in tissue preparation are introduced, this method may represent an approach 
that may become a standard assay for tissue biospecimens. 
6. Changes in the clinical arena warranting changes in biospecimen 
preparation 
Although the technique of cold-PCR will prove very useful in the evaluation of tumor 
specimens for specific mutations, its application or modification to whole genome profiling 
is unknown. Despite an ever expanding database of information that is characterizing 
oncogenesis, there still remains a significant amount of knowledge to be gained. A recent 
initiative to correlate the molecular signatures of tumor tissue specimens with the 
corresponding cancer patient’s clinical parameters underscores the need to identify 
biomarkers that will aid in cancer care. As such, the tissue biospecimen will continue to play 
a significant role in cancer diagnosis and treatment. One lesson that is becoming 
increasingly more apparent is that material that is not fixed serves as the best medium from 
which to start (De Rienzo, 2010 and Jimeno, 2010). This is a reiteration of what has 
previously been documented, but applied to actual biospecimens. The nature of the unfixed 
specimen in the form of fine-needle aspirates however, has one major drawback. The 
technique of fine needle aspiration involves inserting a needle into a mass, and pulling the 
needle in and out of the mass so that tissue fragments are obtained. Since the tool is a 
needle, the tissue fragments are minute. Obtaining a diagnosis based on cytology requires 
extensive training in pathology and its subspecialty, cytopathology. Without the 
architecture, the presence of malignant cells can be diagnosed, but the diminutive nature of 
the specimen sometimes precludes assigning what type of tumor it is. This is particularly 
true for tumors of the lung, where a process similar to fine needle aspiration, in terms of 
quantities of cells recovered, is performed. Whether the procedure is a bronchoscopy with 
material obtained as washings or brushings, or a trans-thoracic needle biopsy, the material 
recovered will be diminutive. Again, the diagnosis of malignancy can be made, but for 
poorly differentiated tumors, the classification into adenocarcinoma, squamous cell 
carcinoma or large cell undifferentiated carcinoma, which is now often requested to help 
guide therapy, will be extremely difficult if next to impossible without a large enough piece 
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of tissue to showcase architecture (Wallace, 2009). For adenocarcinoma, the presence of five 
or more vacuoles in two consecutive high power fields is required to differentiate 
adenocarcinoma from large cell undifferentiated carcinoma. However, the diminutive 
nature of these specimens may not even fulfill this size criterion. If not enough material is 
available to make a definitive diagnosis, the patient may require another invasive procedure 
that may aim to get tissue instead of cells. A similar situation is occurring with the biopsy of 
small kidney tumors where cryoablation instead of resection will be performed.  Although 
attempts to obtain tissue so that a histologic diagnosis can be made, often times the 
specimen is too small and not recovered after tissue processing. The absence of an 
established diagnosis means that should another mass lesion arise in a patient treated by 
cryoablation, it will not be known if the mass represents a metastatic or primary tumor 
Although tumors of unknown origin can be worked up through conventional 
immunohistochemistry, the absence of a previous diagnosis incurs additional costs for this 
work-up. Thus, at today’s medical environment, a histologic diagnosis is still imperative, 
and thus in order to optimally process any specimens in the near future, tools will need to 
be developed that  are capable of allowing the evaluation of these cells at both the cytologic 
and molecular level. 
In order to circumvent the problem of enabling a diagnosis on small biopsy specimens all 
the while providing some material for molecular analysis, investigators have begun 
designing platforms capable of recovering specific subsets of cells from clinical specimens 
(Weigum, 2010, Wan, 2010, and Sun, 2010). These platforms are ideal for taking on the 
problems of small amounts of cells or tissues. Although immunohistochemistry is an 
extremely useful diagnostic tool in the laboratory, the amount of tissue used per assay is 
significant. When a battery of stains is needed to be performed, each 4 or 5 micron thick 
section may end up exhausting the amount of recoverable tissue. Precious tissue can also be 
lost at the microtome step, where some material may be lost just due to the process of 
aligning the  block and blade. Flow cytometry has been used extensively for years for 
hematologic malignancies, but its requirement for ample amounts of starting material 
negate its consideration as a tool for biopsy specimens.  Thus, platforms based on 
microfluidics appear to be best suited to interrogate these small biopsy specimens. Using 
techniques similar to the one previously described above that help enrich for targeted cells, 
these enriched cell populations can then be introduced to a microfluidic platform for 
subsequent evaluation. One noticeable limitation of these platforms however, is the absence 
of the ability to visually evaluate these cells. Although the enrichment approach previously 
described is capable of selecting for epithelial cells from the heterogeneous cell population 
that comprises tissue, the epitope recognized by the ber-EP4 antibody can be present in both 
non-neoplastic and malignant epithelial cells. Thus, until plasma membrane proteins are 
identified and characterized that are specific for either normal or neoplastic epithelial cells, 
enrichment is limited to epithelial cells. This is not so much a limitation in certain tumors 
like colonic adenocarcinomas, where the tumor mass effaces the surrounding tissue so that 
it is composed of tumor epithelial cells and surrounding stroma, but will not be as effective 
in other tumors like the prostate, where the tumor cells infiltrate between normal prostatic 
glands and stroma. For microfluidic platforms, the need to visualize cells will allow 
investigators whether to attribute molecular findings appropriately to neoplastic cells or not. 
At the clinical level, the ability to visualize cells allows for a diagnosis, and determination 
whether the biopsy contains tumor cells and thus is representative of a mass versus no 
tumor cells and therefore not representative of a mass.  
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In the development of such a platform, cytologic examination plays the vital role of 
stratifying whether the cells are tumor or not. Identifying the type of tumor is not so vital as 
the cells, or specifically their contents, can be interrogated through a variety of downstream 
assays. The platform needs to be designed such that the cells are not permanently 
immobilized on the glass slide. Once visualized, they should either be able to be eluted out 
as intact cells, lysed so that the molecules from them can be assayed, or have a lab-on-a chip 
assay integrated to a portion of the slide. Thus, such a microfluidic platform should allow 
for conventional cytologic based examination for screening purposes, followed by molecular 
interrogation for tumor designation.  A period of molecular annotation will take place 
within the next decade wherein reliable biomarkers will be discovered and validated for 
specific tumor types. The transition to molecular identification of tumor tissue has already 
begun and has shown early success in helping determine the site of origin in several 
instances (Ismael, 2006, Greco, 2010, and Monzon, 2010). Molecular tumor classification is 
not yet a reality, with histologic examination still the gold standard for diagnosis (Kotsakis, 
2010). However, in the next decade, when molecular analysis of tumor specimens will occur 
concurrent with histologic examination, a gradual shift in emphasis may occur. With 
Personalized Medicine, the identification of target molecules may eventually become more 
important for cancer treatment than histology. 
6.1 An integrated approach to optimize the biospecimen for cancer care 
Taking into consideration all the factors that may bias the macromolecular profiles of a 
specimen, a tentative approach can be postulated that would recover cells bearing the most 
similar molecular disposition to their in vivo counterparts from clinical material. To address 
preanalytical bias, the specimen most suited for analysis may be the biopsy. Clinically, the 
patient undergoing a biopsy of a tumor would not be subjected to the depth of anesthesia 
that the patient undergoing a surgical resection would be for the same tumor. The degree of 
preparation of the patient is less, with the process most often an out-patient procedure. 
Therefore, confounding issues that potentially could influence, but are hard to confirm, the 
molecular profile of a cell, like administration of intravenous fluids, antibiotics and anxiety 
to name just a few, are not introduced (Compton, 2006).  For issues related to warm 
ischemia, the short time required to obtain a biopsy is also preferred to the comparatively 
longer time required to excise a portion of organ with tumor (Schlomm, 2008). Once the 
biopsy is obtained, the next step would be sample stabilization, an attempt to immediately 
try to preserve the molecules within the cells. For the more labile molecules like RNA, this 
can be achieved by immersing the specimen in RNA Later (Mutter, 2004) or for proteins, 
through heat denaturation (Svensson, 2008). For the latter, the use of heat inactivation helps 
to preserve post-translational modifications, a form of intercellular signaling with a 
transient time frame within proteins that can be lost or altered during cold ischemia, or the 
period after extirpation (Rountree, 2010). Once stabilized, the cells should be disaggregated 
from the tissue and unwanted elements and contaminating normal cells eliminated through 
some form of enrichment. It should be noted that at no point in this proposed procedure 
fixation with formaldehyde is involved. The cells then should be examined cytologically, to 
confirm that the targeted cells are indeed present, that they are enriched and to what 
percentage they constitute the sample.  This should be done on some fluidic based platform, 
so that these same cells can be further examined at the molecular level after microscopic 
diagnostic evaluation. The cells are then eluted and their contents extracted for downstream 
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molecular analysis. Alternatively, other methods may develop wherein diagnostics can be 
performed on the immobilized cell. Through the development of the above protocol, the 
maximal amount of informative data can be extracted from the biospecimen, with a 
combination of traditional anatomic (cytologic) related diagnostics and future molecular 
interrogation for treatment guidance obtained from an optimally recovered specimen. 
6.2 Biospecimens as the focal point of cancer care 
The development of a platform capable of enriching unfixed, preserved tumor cells from 
tissue specimens will enhance clinical research. For some years now it has been known that 
one of the major obstacles to progression in the post-genomic era has been the absence of 
high quality biospecimens. An attempt in the previous decade to obtain 500 cases each of 
specific types of brain, lung and ovarian cancer for gene sequencing initially failed at the 
accrual stage. Although archives in pathology departments have numerous amounts of 
preserved tissue specimens, issues with percentage of tumor content, necrosis or even 
proper consent have become factors preventing their use at a national level. Differences in 
the procurement, handling and storage of samples may also play a role in the differences 
noted between similar tumors from different institutions.  Nevertheless, the National Cancer 
Institute has embarked on an initiative to address those issues related to poor biospecimen 
procurement and to rectify them. The need for high quality biospecimens is reflected in their 
incorporation in innovative study designs for clinical trials, like the new phase 0 trial. In this 
new type of study, the need for patient tumor tissue is necessary in order to determine the 
biological effectiveness of the therapeutic agent being tested. In phase 1 trials the need for 
high quality biospecimens is also warranted, to match the administration of specific agents 
to patients possessing a specific molecular signature, deemed through previous 
experimentation, to be the target of those agent(s).  This approach identifies useful 
therapeutic agents in a subset cohort from the general cancer population, where if an 
empiric approach had been used, the agent may not have resulted in a significant enough 
number of patients to warrant further testing. Molecular testing should also be able to 
identify patients who will be resistant to certain agents, thus guiding the clinician to 
alternative approaches and avoiding any unwarranted side effects and unnecessary costs.  
In the future, the tissue biospecimen will serve many roles, with two being the basis of 
future molecular, proteomic and/or metabolomic  research and the other being the starting 
point for the treatment of the cancer patient. The development of newer biotechnological 
tools will certainly result in a continuing evolution of the tissue biospecimen’s role in the 
treatment of cancer. 
7. Conclusions 
The role of tissue biospecimens in cancer care has evolved over time from observation and 
little impact, to anatomic and molecular diagnostics with high impact on guidance of clinical 
treatment. This evolution has come about based on the changes in the evaluation of the 
specimen, from humble beginnings wherein only the gross anatomic features were noted in 
malignant tissue and the patient’s clinical course observed, to the biotechnological 
revolution and the high throughput capabilities created that can profile molecular 
alterations within cells, identify therapeutic targets and selectively lead to the 
administration of reagents best suited for each individual cancer patient.  Advances in 
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science continue to influence the evaluation of the biospecimen, with an urgent need to 
develop and adapt newer approaches capable of maximizing the amount of informative 
data that can be derived from these samples. The importance of the tissue biospecimen in 
the care of the cancer patient has grown dramatically. It is safe to assume its role in the care 
of the cancer patient of the near future will become even more vital than it is today. 
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